| Trial ID: | L6309 |
| Source ID: | NCT01455909
|
| Associated Drug: |
Itca 650 60 Mcg/Day
|
| Title: |
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: ITCA 650 60 mcg/day|DRUG: sitagliptin
|
| Outcome Measures: |
Primary: Change in HbA1c, 39-week treatment period followed by 65-week extension period, 39 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Intarcia Therapeutics
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2013-02
|
| Completion Date: |
2014-07
|
| Results First Posted: |
|
| Last Update Posted: |
2012-12-25
|
| Locations: |
Intarcia Therapeutics, Inc, Hayward, California, 94545, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01455909
|
